Document Detail


Excess of Solid Cancers After Prasugrel: The Food and Drug Administration Outlook.
MedLine Citation:
PMID:  20634669     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The TRITON-TIMI 38 was a head-to-head trial to assess the efficacy and safety of the experimental antiplatelet agent prasugrel versus standard care with clopidogrel on top of aspirin. Besides some early ischemic protection at the expense of growing over time overwhelming bleeding disadvantage, prasugrel-treated patients experienced significantly higher cancer rates. Recently, the Food and Drug Administration (FDA) issued a Prasugrel Second Review, a detailed 357-page document presenting realistic outlook on various aspects of the TRITON trial including distributions of different cancers between treatment arms. The comprehensive FDA analysis revealed that some preclinical but especially human data overwhelmingly indicate excessive cancer risks after prasugrel. Indeed, despite excellent baseline balance, prasugrel-treated patients experienced extra cancer-related deaths, 27% higher risks for new cancers occurrences, and 36.8% increase of new solid malignant cancers. The FDA report concluded that cancer risks after prasugrel are real, especially high in women, and after 4 months of therapy at least for solid highly metastatic cancers. These unexpected findings may be explained by disruption of tumor-platelet aggregates by chronic profound oral platelet inhibition causing extensive dissemination of initially silent tumors. Since prasugrel gained regulatory approval, the alarming cancer data should be confirmed in further specifically designed trial and carefully assessed in large registries.
Authors:
Victor Serebruany; James Floyd; Derek Chew
Related Documents :
1301129 - The quality of life committee of the clinical trials group of the national cancer insti...
12161079 - A comment on futility monitoring.
16172199 - Management of patients with adrenal cancer: recommendations of an international consens...
16906509 - Proceedings of a workshop: bridging the gap in care and addressing participation in cli...
25244109 - An improved high yield total synthesis and cytotoxicity study of the marine alkaloid ne...
22556269 - Role of the tripartite motif protein 27 in cancer development.
2844479 - The protean manifestations of familial polyposis coli.
17956159 - Uptake and gene expression with antitumoral doses of iodine in thyroid and mammary glan...
17717129 - Genomic profiling of circulating plasma rna for the analysis of cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2010-7-10
Journal Detail:
Title:  American journal of therapeutics     Volume:  -     ISSN:  1536-3686     ISO Abbreviation:  -     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-7-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD; 2Department of Medicine, Division of Cardiology, University of Washington, Seattle, WA; and 3Department of Cardiovascular Medicine, Flinders University, Adelaide, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sudden death associated with Meigs syndrome: an autopsy case report.
Next Document:  Intraoperative administration of clevidipine to prevent vasospasm after radial and internal mammary ...